Strategic Transformation - The company is focusing on high-growth handheld markets aligned with opioid crisis response, defense budgets, and border security[9] - The company divested its biopharma desktop portfolio to REPLIGEN for $70 million in cash[11] - The company is targeting adjusted EBITDA profitability by Q4 2025 and cash flow positivity in 2026, driven by improved gross margins and streamlined operations[9] Financial Performance and Guidance - The company's revenue for the last twelve months as of June 30th was $54 million[15] - The company's cash balance as of June 30th was $119 million[15] - The company projects revenue from continuing operations to be between $54 million and $56 million in 2025, representing a year-over-year growth of +13% to +17%[43] - The company anticipates a return to 20%+ growth with defined catalysts[43] - The company's adjusted gross margin is expected to be in the mid-to-high 50% range[43] - Recurring revenue accounted for $9.1 million, or 37%, of total revenue in YTD 2025[45] Growth Catalysts - Equipment modernization, specifically replacing outdated FTIR devices, presents a 15,000-unit growth opportunity[40] - The launch of the next-generation MX908 device is expected to generate a replacement cycle[40] - The U S Department of Defense AVCAD program partnership represents a growth catalyst, with potential for >$10 million per year in revenue[40]

Strategic Transformation - 908 Devices shifted its focus to high-growth handheld markets, aligning with trends in opioid crisis response, defense budgets, and border security[9] - The company divested its biopharma desktop portfolio to REPLIGEN for $70 million in cash, nearly doubling its balance sheet cash[11] - 908 Devices is targeting adjusted EBITDA profitability by Q4 2025 and cash flow positivity in 2026, driven by improved gross margins and streamlined operations[9] Financial Performance & Guidance - As of March 31, 2025, 908 Devices had $124 million in cash and $52 million in revenue for the last twelve months (LTM)[15] - Q1 2025 recurring revenue was $44 million, representing 37% of total revenue, with a year-over-year growth of 59%[41] - The company's 2025 revenue guidance from continuing operations is $53 million to $55 million, representing a year-over-year growth of +11% to +15%[39] - 908 Devices anticipates an adjusted EBITDA positive by Q4 2025 and expects to have a year-end cash balance of over $110 million[39] - Adjusted gross margin for Q1 2025 was 54%, an increase of 75 basis points year-over-year[41] Growth Catalysts - Equipment modernization, specifically replacing outdated FTIRs, presents a 15,000-unit replacement opportunity[45] - The launch of the next-generation MX908 device is expected to drive enterprise placement wins and generate a replacement cycle from the existing >2,800 MX devices fielded[36] - The U S Department of Defense AVCAD program anticipates an award for full-rate manufacturing, potentially generating >$10 million in annual revenue starting in 2026[37, 45]

MAY 2025 Forward looking statements / Non-GAAP financial measures Analysis at the speed of life This presentation and the accompanying oral presentation (this "presentation") contain forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements may relate to, but are not limited to, expectations of future results of operations or financial performance of 908 Devices Inc. ( ...